<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346057</url>
  </required_header>
  <id_info>
    <org_study_id>8616-145</org_study_id>
    <secondary_id>2017-000187-15</secondary_id>
    <secondary_id>MK-8616-145</secondary_id>
    <nct_id>NCT03346057</nct_id>
  </id_info>
  <brief_title>Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)</brief_title>
  <official_title>A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuronium Bromide in American Society of Anesthesiologists (ASA) Class 3 or 4 Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the safety of sugammadex for the reversal of&#xD;
      neuromuscular blockade (NMB) induced by neuromuscular blockade agents (NMBA) rocuronium or&#xD;
      vecuronium in adult American Society of Anesthesiologists (ASA) Physical Status Class 3 and 4&#xD;
      participants. The primary objectives of the study are to characterize the incidence of&#xD;
      treatment emergent sinus bradycardia, treatment emergent sinus tachycardia, or other&#xD;
      treatment emergent cardiac arrhythmias after administration of sugammadex and to evaluate the&#xD;
      general safety of sugammadex in a population of ASA Class 3 and 4 participants in a surgical&#xD;
      setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Actual">September 4, 2019</completion_date>
  <primary_completion_date type="Actual">September 4, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events</measure>
    <time_frame>Up to approximately 35 minutes post-administration</time_frame>
    <description>The percentage of participants experiencing treatment-emergent sinus bradycardia events was identified with continuous electrocardiogram (ECG) monitoring. Treatment-emergent sinus bradycardia were defined as a heart rate &lt;60 bpm that has also decreased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus bradycardia events may or may not have been considered an adverse event (AE), as determined by investigator judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events</measure>
    <time_frame>Up to approximately 35 minutes post-administration</time_frame>
    <description>The percentage of participants experiencing treatment-emergent sinus tachycardia events was identified with continuous ECG monitoring. Treatment-emergent sinus tachycardia is defined as a heart rate ≥100 bpm that has also increased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus tachycardia events may or may not have been considered an AE, as determined by investigator judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events</measure>
    <time_frame>Up to approximately 35 minutes post-administration</time_frame>
    <description>The percentage of participants experiencing other treatment-emergent cardiac arrhythmia events was identified with continuous ECG monitoring. Other treatment-emergent cardiac arrhythmias were defined as new or worsening arrhythmias (e.g., atrial fibrillation, atrial tachycardia, ventricular fibrillation, or ventricular tachyarrhythmia), sustained for at least 1 minute after administration of study intervention. Worsening arrhythmia events may or may not have been considered an AE, as determined by investigator judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing an Adverse Event (AE) Up To 7 Days After Administration of Study Intervention</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>As per the protocol primary analysis, the percentage of participants experiencing an AE up to 7 days after administration of study intervention was reported. An AE was defined as any untoward medical occurrence in a participant which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing a Serious Adverse Event (SAE) Up To 7 Days After Administration of Study Intervention</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>As per the protocol primary analysis, the percentage of participants experiencing an SAE up to 7 days after administration of study intervention was reported. An SAE was an adverse event that: resulted in death; was life threatening; resulted in persistent or significant disability or incapacity; resulted in or prolonged an existing inpatient hospitalization; was a congenital anomaly or birth defect; was an other important medical event, was a cancer; or was associated with an overdose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing an Event of Clinical Interest (ECI) Up To 7 Days After Administration of Study Intervention</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>As per the protocol primary analysis, the percentage of participants experiencing an ECI up to 7 days after administration of study intervention was reported. ECIs were a discrete set of both AEs and SAEs, specifically designated as such for the trial. For the purposes of this investigation, ECIs included 1) drug-induced liver injury; 2) clinically-relevant arrhythmias, inclusive of bradycardia and tachycardia defined as events necessitating intervention, as determined by investigator judgment; and 3) instances of hypersensitivity and/or anaphylaxis adjudicated by an external expert Adjudication Committee. A participant could have experienced more than one type of ECI.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">344</enrollment>
  <condition>Reversal of Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Sugammadex 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex 2 mg/kg administered as a single intravenous (IV) dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex 4 mg/kg administered as a single IV dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 16 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex 16 mg/kg administered as a single IV dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine + Glycopyrrolate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 2 mg/kg</intervention_name>
    <description>Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex 2 mg/kg for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.</description>
    <arm_group_label>Sugammadex 2 mg/kg</arm_group_label>
    <other_name>MK-8616</other_name>
    <other_name>Bridion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 4 mg/kg</intervention_name>
    <description>Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 4 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.</description>
    <arm_group_label>Sugammadex 4 mg/kg</arm_group_label>
    <other_name>MK-8616</other_name>
    <other_name>Bridion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 16 mg/kg</intervention_name>
    <description>Following administration of NMBA (Rocuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 16 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.</description>
    <arm_group_label>Sugammadex 16 mg/kg</arm_group_label>
    <other_name>MK-8616</other_name>
    <other_name>Bridion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine + Glycopyrrolate</intervention_name>
    <description>Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Neostigmine (50 μg/kg; 5 mg maximum) and Glycopyrrolate (10 μg/kg; 1 mg maximum) for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.</description>
    <arm_group_label>Neostigmine + Glycopyrrolate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>To achieve NMB, participants received steroidal NMBA Rocuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.</description>
    <arm_group_label>Neostigmine + Glycopyrrolate</arm_group_label>
    <arm_group_label>Sugammadex 16 mg/kg</arm_group_label>
    <arm_group_label>Sugammadex 2 mg/kg</arm_group_label>
    <arm_group_label>Sugammadex 4 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vecuronium</intervention_name>
    <description>To achieve NMB, participants received steroidal NMBA Vecuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.</description>
    <arm_group_label>Neostigmine + Glycopyrrolate</arm_group_label>
    <arm_group_label>Sugammadex 2 mg/kg</arm_group_label>
    <arm_group_label>Sugammadex 4 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a body mass index (BMI) &lt; 40 kg/m2.&#xD;
&#xD;
          -  Is categorized as ASA Physical Status Class 3 or 4, as determined by the Investigator.&#xD;
&#xD;
          -  Has a planned surgical procedure that requires NMB with either rocuronium or&#xD;
             vecuronium.&#xD;
&#xD;
          -  Has a planned surgical procedure (e.g., gastrointestinal, urologic, or laparoscopic)&#xD;
             that in the opinion of the investigator does not preclude maintenance of moderate or&#xD;
             deep depth of NMB throughout the case.&#xD;
&#xD;
          -  If female who is not of reproductive potential, is one of the following: (1)&#xD;
             postmenopausal; (2) has had a hysterectomy and/or bilateral oophorectomy, bilateral&#xD;
             salpingectomy, or bilateral tubal ligation/occlusion at least 6 weeks prior to&#xD;
             screening; (3) has a congenital or acquired condition that prevents childbearing; or&#xD;
             (4) is undergoing surgical sterilization (e.g., hysterectomy or tubal ligation) as the&#xD;
             planned surgical procedure associated with participation in this study.&#xD;
&#xD;
          -  If female who is sexually active and of child-bearing potential, agrees to use a&#xD;
             medically accepted method of contraception through seven days after receiving&#xD;
             protocol-specified medication. Abstinence (relative to heterosexual activity) can be&#xD;
             used as the sole method of contraception if it is consistently employed as the&#xD;
             subject's preferred and usual lifestyle and if considered acceptable by local&#xD;
             regulatory agencies and Ethics Review Committees/Institutional Review Boards.&#xD;
&#xD;
          -  Is able to provide (or the participant's legally authorized representative, in&#xD;
             accordance with local requirements), written informed consent for the trial. The&#xD;
             participant or legally authorized representative may also provide consent for Future&#xD;
             Biomedical Research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a pacemaker or automatic implantable cardioverter-defibrillator that precludes the&#xD;
             assessment of bradycardia or arrhythmias.&#xD;
&#xD;
          -  Has a medical condition or surgical procedure that precludes reversal of neuromuscular&#xD;
             block at the end of surgery.&#xD;
&#xD;
          -  Has a neuromuscular disorder(s) that may affect neuromuscular block and/or trial&#xD;
             assessments.&#xD;
&#xD;
          -  Is dialysis-dependent or has severe renal insufficiency, defined as estimated&#xD;
             creatinine clearance of &lt;30 mL/min.&#xD;
&#xD;
          -  Has or is suspected of having a personal history or family history (parents,&#xD;
             grandparents, or siblings) of malignant hyperthermia.&#xD;
&#xD;
          -  Has or is suspected of having an allergy (e.g., hypersensitivity and/or anaphylactic&#xD;
             reaction) to study treatments or its/their excipients, to opioids/opiates, muscle&#xD;
             relaxants or their excipients, or other medication(s) used during general anesthesia.&#xD;
&#xD;
          -  Has received or is planned to receive toremifene within 24 hours before or within 24&#xD;
             hours after study medication administration.&#xD;
&#xD;
          -  Has any condition that would contraindicate the administration of study medication.&#xD;
&#xD;
          -  Is pregnant, is attempting to become pregnant, or is lactating.&#xD;
&#xD;
          -  Is currently participating in or has participated in an interventional clinical trial&#xD;
             (including any other current or ongoing trial with a sugammadex treatment arm) with an&#xD;
             investigational compound or device within 30 days of signing the informed consent form&#xD;
             of this current trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama - Birmingham ( Site 1046)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Banner Medical Center ( Site 1019)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center ( Site 1029)</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center ( Site 1001)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Memorial Hospital ( Site 1007)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center ( Site 1050)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University ( Site 1057)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation ( Site 1005)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital ( Site 1039)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital, Royal Oak ( Site 1034)</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital- Columbia MO ( Site 1060)</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health Care ( Site 1022)</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jersey Shore University Medical Center ( Site 1058)</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital [New Brunswick, NJ] ( Site 1017)</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital - Memorial ( Site 1016)</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clin Foundation ( Site 1032)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital ( Site 1004)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140-5103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center ( Site 1033)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hermann Drive Surgical Center ( Site 1021)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zablocki VA Medical Center ( Site 1011)</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Krankenhaus Dornbirn ( Site 1151)</name>
      <address>
        <city>Dornbirn</city>
        <state>Voralberg</state>
        <zip>6850</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch ( Site 1152)</name>
      <address>
        <city>Feldkirch</city>
        <zip>6800</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sozialmedizinisches Zentrum Ost - Donauspital ( Site 1150)</name>
      <address>
        <city>Wien</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitets hospital ( Site 1252)</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg og Frederiksberg Hospital ( Site 1250)</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet ( Site 1253)</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Viborg ( Site 1254)</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar Technische Universitaet Muenchen ( Site 1350)</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum am Steinenberg Reutlingen ( Site 1352)</name>
      <address>
        <city>Reutlingen</city>
        <zip>72764</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephs-Hospitals Warendorf ( Site 1351)</name>
      <address>
        <city>Warendorf</city>
        <zip>48231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <results_first_submitted>August 24, 2020</results_first_submitted>
  <results_first_submitted_qc>October 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2020</results_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>arrhythmia, bradycardia, neuromuscular blocking agents, surgery, tachycardia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Vecuronium Bromide</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03346057/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of 344 participants randomized to the study, 331 received at least one dose of study treatment (All Treated Population) and were evaluable for all safety analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sugammadex 2 mg/kg</title>
          <description>Sugammadex 2 mg/kg administered as a single intravenous (IV) dose</description>
        </group>
        <group group_id="P2">
          <title>Sugammadex 4 mg/kg</title>
          <description>Sugammadex 4 mg/kg administered as a single IV dose</description>
        </group>
        <group group_id="P3">
          <title>Sugammadex 16 mg/kg</title>
          <description>Sugammadex 16 mg/kg administered as a single IV dose</description>
        </group>
        <group group_id="P4">
          <title>Neostigmine + Glycopyrrolate</title>
          <description>Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible For Study - Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Renal Insufficiency - Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization Mistake - Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Sugammadex 2 mg/kg</title>
          <description>Sugammadex 2 mg/kg administered as a single intravenous (IV) dose</description>
        </group>
        <group group_id="B2">
          <title>Sugammadex 4 mg/kg</title>
          <description>Sugammadex 4 mg/kg administered as a single IV dose</description>
        </group>
        <group group_id="B3">
          <title>Sugammadex 16 mg/kg</title>
          <description>Sugammadex 16 mg/kg administered as a single IV dose</description>
        </group>
        <group group_id="B4">
          <title>Neostigmine + Glycopyrrolate</title>
          <description>Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="112"/>
            <count group_id="B3" value="68"/>
            <count group_id="B4" value="53"/>
            <count group_id="B5" value="344"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.5" spread="10.7"/>
                    <measurement group_id="B2" value="67.8" spread="12.1"/>
                    <measurement group_id="B3" value="69.4" spread="10.0"/>
                    <measurement group_id="B4" value="66.6" spread="10.9"/>
                    <measurement group_id="B5" value="68.5" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="332"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="325"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participant Stratifications</title>
          <description>Participants were stratified by neuromuscular blockade agent (NMBA, rocuronium or vecuronium) and American Society of Anesthesiologists (ASA) Class which ranges from ASA 1 (Normal healthy patient) to ASA 6 (Declared brain-dead patient whose organs are being removed for donor purposes). Higher ASA class with other factors (surgery type, frailty, and deconditioning) help predict greater perioperative risk. Participants were graded as ASA 3 if participants had severe systematic disease and as ASA 4 if participants had severe systematic disease that was a constant threat to the life.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Rocuronium, ASA Class 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rocuronium, ASA Class 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vecuronium, ASA Class 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vecuronium, ASA Class 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events</title>
        <description>The percentage of participants experiencing treatment-emergent sinus bradycardia events was identified with continuous electrocardiogram (ECG) monitoring. Treatment-emergent sinus bradycardia were defined as a heart rate &lt;60 bpm that has also decreased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus bradycardia events may or may not have been considered an adverse event (AE), as determined by investigator judgment.</description>
        <time_frame>Up to approximately 35 minutes post-administration</time_frame>
        <population>All randomized participants who received at least one dose of study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex 2 mg/kg</title>
            <description>Sugammadex 2 mg/kg administered as a single intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>Sugammadex 4 mg/kg</title>
            <description>Sugammadex 4 mg/kg administered as a single IV dose</description>
          </group>
          <group group_id="O3">
            <title>Sugammadex 16 mg/kg</title>
            <description>Sugammadex 16 mg/kg administered as a single IV dose</description>
          </group>
          <group group_id="O4">
            <title>Neostigmine + Glycopyrrolate</title>
            <description>Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events</title>
          <description>The percentage of participants experiencing treatment-emergent sinus bradycardia events was identified with continuous electrocardiogram (ECG) monitoring. Treatment-emergent sinus bradycardia were defined as a heart rate &lt;60 bpm that has also decreased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus bradycardia events may or may not have been considered an adverse event (AE), as determined by investigator judgment.</description>
          <population>All randomized participants who received at least one dose of study intervention</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="7.4"/>
                    <measurement group_id="O4" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Miettinen &amp; Nurminen method stratified by neuromuscular blocking agent (NMBA) and American Society of Anesthesiologists (ASA) class was used to provide estimated between-treatment difference, 95% confidence interval, and p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Stratified Miettinen &amp; Nurminen method</method>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>-6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.5</ci_lower_limit>
            <ci_upper_limit>-0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference, 95% confidence interval, and p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>Stratified Miettinen &amp; Nurminen method</method>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>-6.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.3</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference, 95% confidence interval, and p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.730</p_value>
            <method>Stratified Miettinen &amp; Nurminen method</method>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>-2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.8</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events</title>
        <description>The percentage of participants experiencing treatment-emergent sinus tachycardia events was identified with continuous ECG monitoring. Treatment-emergent sinus tachycardia is defined as a heart rate ≥100 bpm that has also increased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus tachycardia events may or may not have been considered an AE, as determined by investigator judgment.</description>
        <time_frame>Up to approximately 35 minutes post-administration</time_frame>
        <population>All randomized participants who received at least one dose of study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex 2 mg/kg</title>
            <description>Sugammadex 2 mg/kg administered as a single intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>Sugammadex 4 mg/kg</title>
            <description>Sugammadex 4 mg/kg administered as a single IV dose</description>
          </group>
          <group group_id="O3">
            <title>Sugammadex 16 mg/kg</title>
            <description>Sugammadex 16 mg/kg administered as a single IV dose</description>
          </group>
          <group group_id="O4">
            <title>Neostigmine + Glycopyrrolate</title>
            <description>Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events</title>
          <description>The percentage of participants experiencing treatment-emergent sinus tachycardia events was identified with continuous ECG monitoring. Treatment-emergent sinus tachycardia is defined as a heart rate ≥100 bpm that has also increased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus tachycardia events may or may not have been considered an AE, as determined by investigator judgment.</description>
          <population>All randomized participants who received at least one dose of study intervention</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="9.3"/>
                    <measurement group_id="O3" value="8.8"/>
                    <measurement group_id="O4" value="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference, 95% confidence interval, and p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Stratified Miettinen &amp; Nurminen method</method>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>-14.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.8</ci_lower_limit>
            <ci_upper_limit>-4.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference, 95% confidence interval, and p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>Stratified Miettinen &amp; Nurminen method</method>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>-12.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.1</ci_lower_limit>
            <ci_upper_limit>-0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference, 95% confidence interval, and p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.158</p_value>
            <method>Stratified Miettinen &amp; Nurminen method</method>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>-9.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.6</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events</title>
        <description>The percentage of participants experiencing other treatment-emergent cardiac arrhythmia events was identified with continuous ECG monitoring. Other treatment-emergent cardiac arrhythmias were defined as new or worsening arrhythmias (e.g., atrial fibrillation, atrial tachycardia, ventricular fibrillation, or ventricular tachyarrhythmia), sustained for at least 1 minute after administration of study intervention. Worsening arrhythmia events may or may not have been considered an AE, as determined by investigator judgment.</description>
        <time_frame>Up to approximately 35 minutes post-administration</time_frame>
        <population>All randomized participants who received at least one dose of study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex 2 mg/kg</title>
            <description>Sugammadex 2 mg/kg administered as a single intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>Sugammadex 4 mg/kg</title>
            <description>Sugammadex 4 mg/kg administered as a single IV dose</description>
          </group>
          <group group_id="O3">
            <title>Sugammadex 16 mg/kg</title>
            <description>Sugammadex 16 mg/kg administered as a single IV dose</description>
          </group>
          <group group_id="O4">
            <title>Neostigmine + Glycopyrrolate</title>
            <description>Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events</title>
          <description>The percentage of participants experiencing other treatment-emergent cardiac arrhythmia events was identified with continuous ECG monitoring. Other treatment-emergent cardiac arrhythmias were defined as new or worsening arrhythmias (e.g., atrial fibrillation, atrial tachycardia, ventricular fibrillation, or ventricular tachyarrhythmia), sustained for at least 1 minute after administration of study intervention. Worsening arrhythmia events may or may not have been considered an AE, as determined by investigator judgment.</description>
          <population>All randomized participants who received at least one dose of study intervention</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference, 95% confidence interval, and p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.637</p_value>
            <method>Stratified Miettinen &amp; Nurminen method</method>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference, 95% confidence interval, and p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.134</p_value>
            <method>Stratified Miettinen &amp; Nurminen method</method>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.6</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference, 95% confidence interval, and p-value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.577</p_value>
            <method>Stratified Miettinen &amp; Nurminen method</method>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.7</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing an Adverse Event (AE) Up To 7 Days After Administration of Study Intervention</title>
        <description>As per the protocol primary analysis, the percentage of participants experiencing an AE up to 7 days after administration of study intervention was reported. An AE was defined as any untoward medical occurrence in a participant which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE.</description>
        <time_frame>Up to 7 days</time_frame>
        <population>All randomized participants who received at least one dose of study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex 2 mg/kg</title>
            <description>Sugammadex 2 mg/kg administered as a single intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>Sugammadex 4 mg/kg</title>
            <description>Sugammadex 4 mg/kg administered as a single IV dose</description>
          </group>
          <group group_id="O3">
            <title>Sugammadex 16 mg/kg</title>
            <description>Sugammadex 16 mg/kg administered as a single IV dose</description>
          </group>
          <group group_id="O4">
            <title>Neostigmine + Glycopyrrolate</title>
            <description>Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing an Adverse Event (AE) Up To 7 Days After Administration of Study Intervention</title>
          <description>As per the protocol primary analysis, the percentage of participants experiencing an AE up to 7 days after administration of study intervention was reported. An AE was defined as any untoward medical occurrence in a participant which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE.</description>
          <population>All randomized participants who received at least one dose of study intervention</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                    <measurement group_id="O2" value="88.8"/>
                    <measurement group_id="O3" value="92.6"/>
                    <measurement group_id="O4" value="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference and 95% confidence interval</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>6.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>18.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference and 95% confidence interval</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>13.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference and 95% confidence interval</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>17.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing a Serious Adverse Event (SAE) Up To 7 Days After Administration of Study Intervention</title>
        <description>As per the protocol primary analysis, the percentage of participants experiencing an SAE up to 7 days after administration of study intervention was reported. An SAE was an adverse event that: resulted in death; was life threatening; resulted in persistent or significant disability or incapacity; resulted in or prolonged an existing inpatient hospitalization; was a congenital anomaly or birth defect; was an other important medical event, was a cancer; or was associated with an overdose.</description>
        <time_frame>Up to 7 days</time_frame>
        <population>All randomized participants who received at least one dose of study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex 2 mg/kg</title>
            <description>Sugammadex 2 mg/kg administered as a single intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>Sugammadex 4 mg/kg</title>
            <description>Sugammadex 4 mg/kg administered as a single IV dose</description>
          </group>
          <group group_id="O3">
            <title>Sugammadex 16 mg/kg</title>
            <description>Sugammadex 16 mg/kg administered as a single IV dose</description>
          </group>
          <group group_id="O4">
            <title>Neostigmine + Glycopyrrolate</title>
            <description>Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing a Serious Adverse Event (SAE) Up To 7 Days After Administration of Study Intervention</title>
          <description>As per the protocol primary analysis, the percentage of participants experiencing an SAE up to 7 days after administration of study intervention was reported. An SAE was an adverse event that: resulted in death; was life threatening; resulted in persistent or significant disability or incapacity; resulted in or prolonged an existing inpatient hospitalization; was a congenital anomaly or birth defect; was an other important medical event, was a cancer; or was associated with an overdose.</description>
          <population>All randomized participants who received at least one dose of study intervention</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                    <measurement group_id="O2" value="7.5"/>
                    <measurement group_id="O3" value="10.3"/>
                    <measurement group_id="O4" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference and 95% confidence interval</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>5.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>14.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference and 95% confidence interval</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.2</ci_lower_limit>
            <ci_upper_limit>9.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference and 95% confidence interval</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.1</ci_lower_limit>
            <ci_upper_limit>12.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing an Event of Clinical Interest (ECI) Up To 7 Days After Administration of Study Intervention</title>
        <description>As per the protocol primary analysis, the percentage of participants experiencing an ECI up to 7 days after administration of study intervention was reported. ECIs were a discrete set of both AEs and SAEs, specifically designated as such for the trial. For the purposes of this investigation, ECIs included 1) drug-induced liver injury; 2) clinically-relevant arrhythmias, inclusive of bradycardia and tachycardia defined as events necessitating intervention, as determined by investigator judgment; and 3) instances of hypersensitivity and/or anaphylaxis adjudicated by an external expert Adjudication Committee. A participant could have experienced more than one type of ECI.</description>
        <time_frame>Up to 7 days</time_frame>
        <population>All randomized participants who received at least one dose of study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex 2 mg/kg</title>
            <description>Sugammadex 2 mg/kg administered as a single intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>Sugammadex 4 mg/kg</title>
            <description>Sugammadex 4 mg/kg administered as a single IV dose</description>
          </group>
          <group group_id="O3">
            <title>Sugammadex 16 mg/kg</title>
            <description>Sugammadex 16 mg/kg administered as a single IV dose</description>
          </group>
          <group group_id="O4">
            <title>Neostigmine + Glycopyrrolate</title>
            <description>Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing an Event of Clinical Interest (ECI) Up To 7 Days After Administration of Study Intervention</title>
          <description>As per the protocol primary analysis, the percentage of participants experiencing an ECI up to 7 days after administration of study intervention was reported. ECIs were a discrete set of both AEs and SAEs, specifically designated as such for the trial. For the purposes of this investigation, ECIs included 1) drug-induced liver injury; 2) clinically-relevant arrhythmias, inclusive of bradycardia and tachycardia defined as events necessitating intervention, as determined by investigator judgment; and 3) instances of hypersensitivity and/or anaphylaxis adjudicated by an external expert Adjudication Committee. A participant could have experienced more than one type of ECI.</description>
          <population>All randomized participants who received at least one dose of study intervention</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With one or more ECIs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="5.6"/>
                    <measurement group_id="O3" value="7.4"/>
                    <measurement group_id="O4" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adjudicated Hypersensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adjudicated Anaphylaxis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically Relevant Bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically Relevant Tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="5.9"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Clinically Relevant Cardiac Arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug Induced Liver Injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The percentage of participants experiencing one or more ECIs was compared between the Sugammadex 2 mg/kg arm and the Neostigmine plus Glycopyrrolate arm. Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference and 95% confidence interval</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.8</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The percentage of participants experiencing one or more ECIs was compared between the Sugammadex 4 mg/kg arm and the Neostigmine plus Glycopyrrolate arm. Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference and 95% confidence interval</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.1</ci_lower_limit>
            <ci_upper_limit>8.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The percentage of participants experiencing one or more ECIs was compared between the Sugammadex 16 mg/kg arm and the Neostigmine plus Glycopyrrolate arm. Miettinen &amp; Nurminen method stratified by NMBA and ASA was used to provide estimated between-treatment difference and 95% confidence interval</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Estimated Difference in percentage</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.5</ci_lower_limit>
            <ci_upper_limit>11.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to approximately 21 days post treatment</time_frame>
      <desc>All-Cause Mortality reported for all randomized participants (N = 344: Sugammadex 2 mg/kg: n = 111, Sugammadex 4 mg/kg: n = 112, Sugammadex 16 mg/kg: n = 68, and Neostigmine + Glycopyrrolate: n = 53). Serious AEs and Other AEs were reported for all randomized participants who received at least 1 dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sugammadex 2 mg/kg</title>
          <description>Sugammadex 2 mg/kg administered as a single intravenous (IV) dose</description>
        </group>
        <group group_id="E2">
          <title>Sugammadex 4 mg/kg</title>
          <description>Sugammadex 4 mg/kg administered as a single IV dose</description>
        </group>
        <group group_id="E3">
          <title>Sugammadex 16 mg/kg</title>
          <description>Sugammadex 16 mg/kg administered as a single IV dose</description>
        </group>
        <group group_id="E4">
          <title>Neostigmine + Glycopyrrolate</title>
          <description>Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Heparin-induced thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gallbladder abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Purulent discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Fascial rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Postoperative delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Urinary retention postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="105"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="107"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="68"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="105"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="107"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="68"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Postoperative hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="66" subjects_affected="58" subjects_at_risk="105"/>
                <counts group_id="E2" events="67" subjects_affected="56" subjects_at_risk="107"/>
                <counts group_id="E3" events="38" subjects_affected="31" subjects_at_risk="68"/>
                <counts group_id="E4" events="31" subjects_affected="27" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

